{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-22-000016","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.395262+00:00","generated_at":"2026-06-27T12:00:21.470131+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q4 2021 non-GAAP EPS $2.49 (+8%), revenue $8.0B +8%; 2022 guidance reaffirmed","bullets":["Q4 revenue $7,999.9M (+8% YoY); non-GAAP EPS $2.49 (+8%).","Full-year revenue $28,318.4M (+15%); non-GAAP EPS $8.16 (+20%).","COVID-19 antibody revenue $1.06B in Q4, $2.24B for full year.","Key growth products (Trulicity, Taltz, Verzenio, Jardiance, Olumiant) contributed 14 ppt revenue growth ex-COVID.","2022 EPS guidance: GAAP $8.00-$8.15, non-GAAP $8.50-$8.65; dividend raised 15%."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-22-000016","json":"https://secwatch.observer/filing/0000059478-22-000016.json","markdown":"https://secwatch.observer/filing/0000059478-22-000016.md","text":"https://secwatch.observer/filing/0000059478-22-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/0000059478-22-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000016/lly-20220203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T12:00:21.470131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}